Preclinical data showing beneficial effects of OGA inhibition on memory performance in mouse models of tauopathy and AD has led to significant clinical interest in OGA inhibitors as a potential treatment for neurodegenerative disorders in patients (Yuzwa et al., 2014; Bartolome-Nebreda et al., 2021; Graham et al., 2014; Hastings et al., 2017; Selnick et al., 2019; Permanne et al., 2022; Wheatley et al., 2019). This evidence concerns the gene OGA and Alzheimer disease.